Tosedostat

Drug Profile

Tosedostat

Alternative Names: CHR-2797

Latest Information Update: 08 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vernalis
  • Developer Azienda Ospedaliera Ospedali Riuniti Marche Nord; CTI BioPharma
  • Class Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Solid tumours

Most Recent Events

  • 03 Feb 2017 Leukaemia and Lymphoma Research Institute and National Cancer Research Institute terminates the AML-LI-1 trial in Acute myeloid leukaemia and Myelodysplastic syndrome (Combination therapy, First line therapy, In elderly) in United Kingdom and Denmark
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in United Kingdom (PO, Capsule)
  • 06 Dec 2015 Efficacy data from a phase II trial in Acute myeloid leukaemia presented at the Annual Meeting of the American Society of Hematology (ASH-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top